Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Pediatr ; 157(2): 271-5, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20394947

ABSTRACT

OBJECTIVE: To validate a 2-tier approach for newborn screening (NBS) of remethylation defects. STUDY DESIGN: The original NBS dried blood spots of 5 patients with a proven diagnosis of a remethylation disorder and 1 patient with biochemical evidence of such disorder were analyzed retrospectively to determine disease ranges for methionine (Met; 4.7-8.1 micromol/L; 1 percentile of healthy population, 11.1 micromol/L), the methionine/phenylalanine ratio (Met/Phe; 0.09-0.16; 1 percentile of healthy population, 0.22), and total homocysteine (tHcy; 42-157 micromol/L; 99 percentile of normal population, 14.7 micromol/L). These preliminary disease ranges showed a sufficient degree of segregation from healthy population data, allowing the selection of cutoff values. A simple algorithm was then developed to reflex cases to a second-tier testing for tHcy, which has been applied prospectively for 14 months. RESULTS: A total of 86 333 NBS samples were tested between January 2007 and March 2008, and 233 of them (0.27%) met the criteria for second-tier testing of tHcy. All cases revealed concentrations of tHcy <15 micromol/L and were considered unaffected. No false-negative results have been reported with a state-wide system based on 2 combined metabolic clinics and laboratories that cover the entire Minnesota population and border areas of neighboring states. CONCLUSIONS: Pending more conclusive evidence from the prospective identification of additional true-positive cases, NBS for remethylation disorders appears to be feasible with existing methodologies, with only a marginal increase of the laboratory workload.


Subject(s)
Metabolism, Inborn Errors/blood , Methylenetetrahydrofolate Reductase (NADPH2)/deficiency , Neonatal Screening/methods , Tandem Mass Spectrometry/methods , Algorithms , Homocysteine/blood , Humans , Infant, Newborn , Metabolism, Inborn Errors/diagnosis , Methionine/blood , Mutation , Phenylalanine/blood , Reference Values , Reproducibility of Results , Retrospective Studies
2.
Nestle Nutr Workshop Ser Pediatr Program ; 62: 81-93; discussion 93-6, 2008.
Article in English | MEDLINE | ID: mdl-18626194

ABSTRACT

Tandem mass spectrometry has been the main driver behind a significant expansion in newborn screening programs. The ability to detect more than 40 conditions by a single test underscores the need to better understand the clinical and laboratory characteristics of the conditions being tested, and the complexity of pattern recognition and differential diagnoses of one or more elevated markers. The panel of conditions recommended by the American College of Medical Genetics, including 20 primary conditions and 22 secondary targets that are detectable by tandem mass spectrometry has been adopted as the standard of care in the vast majority of US states. The evolution of newborn screening is far from being idle as a large number of infectious, genetic, and metabolic conditions are currently under investigation at variable stages of test development and clinical validation. In the US, a formal process with oversight by the Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children has been established for nomination and evidence-based review of new candidate conditions. If approved, these conditions could be added to the uniform panel and consequently pave the way to large scale implementation.


Subject(s)
Infant Nutrition Disorders/diagnosis , Infant Nutrition Disorders/genetics , Mass Screening , Tandem Mass Spectrometry/methods , Humans , Infant, Newborn , Sensitivity and Specificity , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...